Aim: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin-bound paclitaxel monotherapy as second-or third-line treatment for non-small-cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement.
INTRODUCTION
Nanoparticle albumin-bound paclitaxel (nab-PTX) showed a significantly higher overall response rate (ORR) than solvent-based paclitaxel (sb-PTX) in combination with carboplatin for patients with nonsmall cell lung cancer (NSCLC) as first-line treatment (33% vs 25%, P = 0.001). The frequency of some serious adverse events (AEs) in the nab-PTX arm, such as peripheral neuropathy and neutropenia, was less than that in the sb-PTX arm. 1 and median time to progression were 30% and 5 months, respectively. 2 In addition, a phase II study of weekly nab-PTX in patients previously treated for advanced NSCLC demonstrated acceptable toxicity and promising activity; ORR and median progression-free survival (mPFS) were 31.7% (95% confidence interval [CI] of 19.3-44.1%) and 4.9 months (95% CI, 2.4-7.4 months), respectively. 3 Epidermal growth factor receptor (EGFR) mutations may be predictive biomarkers for the effects of cytotoxic chemotherapy, according to some phase III randomized studies comparing the efficacy of EGFR-tyrosine kinase inhibitors with cytotoxic chemotherapies in NSCLC patients. In the INTEREST study, the ORR of docetaxel (DOC) was 21.1% for the EGFR mutant, whereas it was 9.8% for wild-type patients. 4 In the V-15-32 study, the ORR of DOC was 46% for the EGFR mutant, whereas it was 13% for wild-type patients. 5 In the TRIB-UTE trial, the progressive disease rate of carboplatin and paclitaxel chemotherapy was 21% for the EGFR mutant, whereas it was 37% for wild-type patients. 6 However, in the DELTA study, comparing erlotinib with DOC in previously treated NSCLC patients, the ORRs of DOC were similar: 17.9% for the EGFR-unselected patients and 20.0% for wild-type patients. 7, 8 As the importance of individualized medicine increases, it is necessary to establish a treatment strategy that takes into consideration the presence or absence of driver mutations, such as EGFR or anaplastic lymphoma kinase (ALK). To date, no clinical trial prospectively examined the efficacy and safety of nab-PTX for previously treated NSCLC patients without EGFR or ALK mutations. We believed that the development of a superior second-line treatment was important for such cases.
With this background, we determined the recommended schedule of weekly nab-PTX in phase I of the study. Subsequently, in phase II, we evaluated the efficacy and safety of nab-PTX with the recommended schedule as second-or third-line treatment for patients with advanced NSCLC without any driver mutation.
PATIENTS AND METHODS

Patients
Patients aged ≥20 years were enrolled in the study. The primary endpoints of phase I were feasibility and determination of the recommended nab-PTX schedule.
Treatment and assessment in phase II
In phase II, nab-PTX was administered according to the recommended schedule determined in phase I until disease progression and unacceptable AEs were observed. The primary endpoint of phase II was ORR and the secondary endpoints were overall survival (OS), PFS and safety. Tumor response was assessed according to the RECIST v1.1.
AEs were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
Statistical analysis
The sample size was calculated according to Simon's optimal and minimax two-stage sequential design. The expected ORR and threshold ORR for this study were assumed to be 15% and 5%, respectively. 9 Given this assumption, calculation of the required number of subjects with = 0.05 (one-sided) and = 0.2 yielded 52 patients; considering that some patients may be ineligible, the planned enrollment number for phase II was set at 55 patients. These 55 patients included patients enrolled in phase I with the recommended schedule. We considered weekly nab-PTX to be an effective treatment regimen, if complete response (CR) or partial response (PR) was confirmed in ≥9 patients from the total of 55.
RESULTS
Phase I
A total of five patients were enrolled in phase I. The patient characteristics in phase I are presented in Table 1 . The recommended schedule of weekly nab-PTX was determined as level -1, because DLT was observed in four of five patients. The contents of DLTs were grade 3/4 neutropenia in three patients (60%) and grade 2 pneumonitis in one patient (20%).
Phase II
A total of 55 patients were enrolled in phase II between April 2014 and July 2016. The patient characteristics in phase II are presented in Table 1 . The median age was 66 years (range, 41-90 years). The proportion of male patients was 72.7% and the PS 0/1/2 was 12/39/4, respectively. Thirty-four (61.8%) patients were administered secondline therapy. Twenty patients (36.3%) previously received DOC treatment. In 21 patients, (38.2%) who previously received both first-and second-line treatments, DOC was most frequently administered as the second-line treatment (52.4%). The proportion of patients with adenocarcinoma and squamous cell carcinoma (Sq) was 34 (61.8%) and 17 (30.9%) patients, respectively.
Efficacy
Treatment efficacy is summarized in Table 2 . All 55 patients were eligible for efficacy analysis. Based on the investigator's assessment, four patients had a PR, and none demonstrated CR, yielding an ORR of 7.3% (95% CI, 2.0-17.6%). Twenty-six patients had stable disease (SD), yielding a disease control rate (DCR: CR + PR + SD) of 54.5% (95% CI, 40.6-68.0%). In addition, subanalysis of clinical concerned factors predicting ORR and DCR was conducted ( Table 3 ). The patients with non-Sq TA B L E 1 Characteristics of patients in the study (n = 60) Phase I (n = 5) Phase II (n = 55) 
Safety
All 55 patients enrolled in the study treatment were eligible for safety analysis. The major treatment-related toxicities are presented in Tables 4 and 5 . The major nonhematologic toxicities (total/grade 3 or more) were peripheral sensory neuropathy (49.1%/1.8%), fatigue (27.3%/0%) and anorexia (27.3%/1.8%). The most frequent treatmentrelated grade 3 or 4 toxicities were neutropenia (36%), febrile neutropenia (5.5%) and pulmonary infection (3.6%). Five patients (9.1%) and one patient received granulocyte-colony-stimulating factor support and erythrocyte transfusion, respectively. Seven patients (13%) discontinued the study treatment because of grade 2 pneumonitis (n = 3), grade 3 AST/ALT elevation (n = 1), grade 4 sepsis (n = 1), grade 3 anorexia (n = 1) and grade 5 adult respiratory distress syndrome (ARDS) (n = 1).
Two deaths (3.6%) were observed during the protocol study. One patient developed grade 5 ARDS on day 26 of the second cycle. 
TA B L E 4 Treatment-related adverse events in phase II of the trial
DISCUSSION
We performed a prospective, multicenter phase I/II study of weekly nab-PTX therapy in patients with advanced NSCLC without EGFR mutations or ALK rearrangement who were previously treated with platinum-doublet chemotherapy. Although the level -1 schedule was not investigated in phase I, the proportion of AEs as the cause of discontinuation of therapy and dose reduction in phase II was 9/55 (16.4%) and 7/55 (13%) patients, respectively. The incidence of nonhematologic toxicities of grade ≥3 with the level -1 schedule was < 5%, except for febrile neutropenia (5.5%). Hematological toxicity was mild, with an incidence of 36.4% for grade ≥3 neutropenia. In contrast, the incidence of grade ≥3 neutropenia was 90.1% and that of febrile neutropenia was 19.1% in the DOC arm of phase III studies in previously treated Japanese patients with advanced NSCLC. 10 Considering these factors, the level -1 schedule was feasible and appropriate in this setting.
Although patients with histology of non-Sq tended to have better ORR in subanalysis, the experimental regimen yielded an ORR of 7.3% (95% CI, 2.0-17.6%) in total, which did not meet the primary endpoint of the study. In other clinical trials involving EGFR-mutated NSCLC patients, ORR was 14.5-31.7%, indicating good efficacy. 3, 11, 12 In the However, DCR, PFS and OS were not lower than those in other trials, where patients with EGFR mutation were included (Table 6) . 3, 11, 12 The argument whether ORR is appropriate to determine the efficiency criteria in second-or third-line treatment is ongoing. Because PFS and OS of patients ≥70 years administered nab-PTX in the CA031 trial tended to be superior to those administered sb-PTX, a phase III trial (ABOUND .70+ trial) was conducted to investigate the efficacy and safety of weekly nab-PTX either continuously or with a 1-week interval, both in combination with carboplatin for patients aged ≥70 years. 13 The study showed that the 1-week break between treatment cycles significantly improved PFS (mPFS was 3. In preclinical data, it was shown that combination therapy with PTX/nab-PTX and angiogenesis inhibitor bevacizumab increased the antitumor effect as compared with PTX/nab-PTX monotherapy. 14 Actually, in advanced gastric cancer, angiogenesis inhibitor ramucirumab + PTX has been statistically significantly prolonged OS compared with PTX alone as a secondary treatment in patients who progressed after platinum-containing chemotherapy, and it is regarded as standard treatment. 15 In the future, it might be necessary to verify the effectiveness and safety of combination therapy of nab-PTX and angiogenesis inhibitor as a second-line chemotherapy in NSCLC.
This study failed to meet predefined primary endpoints for patients with advanced NSCLC, although the PFS and OS were comparable with those in previous reports and toxicity was acceptable. The weekly nab-PTX was not a promising treatment for NSCLC patients without EGFR
or ALK mutations as a second-or third-line treatment setting.
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